证券代码：002250 证券简称：联化科技 公告编号：2025-044 联化科技股份有限公司 关于受让控股子公司郡泰医药20%股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 1、2025年10月9日，联化科技股份有限公司（以下简称"公司"或"买方"） 与张立清、乐和友、董伙祥、陈川、阮建奇和张涛（以下合称为"卖方"）签订 了《股权转让合同》，决定以自有资金受让卖方所持有的湖北郡泰医药化工有限 公司（以下简称"郡泰医药"）20%股权，受让总金额为2,500.00万元人民币（以 下简称"本次受让"）。本次股权受让完成后，公司将持有郡泰医药100%股权。 2、本次受让已经公司第九届董事会第二次会议审议批准，无需提交公司股 东会审议。 3、本次受让不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组，无须征得债权人或其他第三方的同意。 二、交易各方基本情况 1、买方基本情况：联化科技股份有限公司是依法设立并有效存续的上市公 司，住所：浙江省台州市黄岩经济开发区永椒路8号，法定代表人王萍。 2、卖方基本情况：张立清、乐和 ...

| | | | | 修订前 | | | | | | | | | | 修订后 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 第 六 | 条 | 公 | 司 | 注 册 | 资 | 本 | 为 | 人民 | 币 | 第 六 | 条 | 公 | 司 | 注 | 册 资 | 本 | 为 | 人民 | 币 | | 911,333,117 | | | 元。 | | | | | | | 899,873,217 | | | 元。 | | | | | | | | 第 二 一 | 十 | 条 | | 公 | 司 | 股 | 份 | 总 数 | 为 | 第 二 十 | | 一 条 | | 公 | 司 | 股 | 份 | 总 数 | 为 | | 911,333,117 | | | | | | 股，公司的股本结构为： | | | | 899,873,217 | | | | | | 股，公司的股本结构为： | | ...

特别提示： 本次新增担保额度为70,000万元，其中为最近一期资产负债率高于70%的控 股子公司Fine Organics Limited新增担保额度不超过等值人民币20,000万元，敬请 投资者关注担保风险。 证券代码：002250 证券简称：联化科技 公告编号：2025-047 联化科技股份有限公司 关于公司为子公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"、"联化科技"）第九届董事会第二 次会议（以下简称"董事会"）审议通过了《关于公司为子公司提供担保额度预 计的议案》，上述担保事项需经公司2025年第二次临时股东会审议批准。现将具 体情况公告如下： 一、新增担保情况 因生产经营和业务发展需要，为了保证公司及子公司经营有序进行，公司拟 根据实际情况为子公司提供70,000万元的新增担保额度，以满足公司子公司经营 的需要。 本次新增担保额度70,000万元，其中为最近一期资产负债率低于70%的控股 子公司新增担保额度不超过50,000万元，为最近一期资产负债率高于70%的控股 子公司新增担 ...

证券代码：002250 证券简称：联化科技 公告编号：2025-048 联化科技股份有限公司 关于公司为临海联化提供担保额度预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 本次新增担保额度为30,000万元，其中为最近一期资产负债率高于70%的控 股子公司临海联化新增担保额度不超过人民币30,000万元，敬请投资者关注担保 风险。 联化科技股份有限公司（以下简称"公司"、"联化科技"）第九届董事会第二 次会议（以下简称"董事会"）审议通过了《关于公司为临海联化提供担保额度预 计的议案》，上述担保事项需经公司2025年第二次临时股东会审议批准。现将具 体情况公告如下： 一、新增担保情况 因生产经营和业务发展需要，为了保证公司及子公司经营有序进行，公司拟 根据实际情况为联化科技（临海）有限公司（以下简称"临海联化"）提供30,000 万元的新增担保额度，以满足公司子公司经营的需要。 本次新增担保额度30,000万元，即为最近一期资产负债率高于70%的控股子 公司新增担保额度不超过等值人民币30,000万元。上述2025年度为临海联化融资 提 ...

证券代码：002250 证券简称：联化科技 公告编号：2025-049 联化科技股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （1）现场会议时间：2025年10月28日15:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年10月28日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为2025年10月28日9:15至15:00的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025年10月21日 7、出席对象： （1）截至2025年10月21日下午收市时在中国证券登记结算公司深圳分公司 登记在册的公司全体股东均有权以本通知公布的方式出席本次股东会，及参加表 决；股东因故不能亲自到会，可书面委托代理人（该代理人不必是公司股东）出 席会议和参加表决； 1、股东会届次：2025年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开 ...

Core Insights - Company is actively developing and collaborating with major domestic clients, focusing on innovative drug development and has a pipeline of clinically promising products in phases II and III [1] - The global CXO service market is projected to grow from approximately $79.4 billion in 2024 to $161.6 billion by 2031, with a CAGR of 10.9% from 2025 to 2031 [1] - Company has established itself as a significant competitor in the CRDMO sector, providing comprehensive services from drug discovery to commercialization [1] Financial Performance - In the first half of 2025, the company's pharmaceutical business revenue reached 1.018 billion yuan, a year-on-year increase of 42.8%, with a gross margin of 42.75% [2] - The company has successfully completed multiple key validation projects, laying a solid foundation for capacity and technology [2] R&D and Technological Advancements - Company has expanded its R&D capabilities beyond traditional small molecules to include amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides, enhancing its market responsiveness [3] - In 2024, the company developed 12 tubular process projects, with 7 achieving continuous production delivery [2][3] - The CRO segment has built capabilities in various technologies, including PROTAC, linker synthesis, and enzyme catalysis, to meet diverse client needs [2][3] Strategic Partnerships and Market Position - Company has deepened R&D collaborations with two global pharmaceutical leaders and partnered with multiple domestic innovative drug companies [2][4] - As a leading provider in the CDMO market for crop protection, the company has established strategic partnerships with five major original research crop protection companies [4] - The company has identified several products with commercialization potential within 3-5 years, supporting long-term business growth [4] Industry Outlook - The company is well-positioned to capitalize on the ongoing recovery in the pharmaceutical R&D and production industry, aiming to strengthen its position in the CXO value chain [5]

Core Viewpoint - The company has established cooperation and close connections with several leading enterprises in the new energy sector, including battery manufacturers and electrolyte manufacturers [1] Group 1 - The company is actively engaging with top enterprises in the new energy industry [1] - Collaboration includes partnerships with both battery and electrolyte manufacturers [1]

证券日报网讯联化科技（002250）9月25日在互动平台回答投资者提问时表示，医药业务上半年度增长 显著，主要系集中发货所致。目前，公司医药事业部已与一批国内外优质客户建立稳定商业联系，业务 合作覆盖范围持续扩大。公司跟随客户业务管线布局公司产品管线，未来随着公司与客户业务的不断深 入，客户专利期内产品的持续推广，公司医药业务将能继续实现增长。 ...

Group 1 - Company Lianhua Technology announced that on September 24, 2025, it will be participating in a research meeting hosted by Galaxy Securities, with senior vice president and secretary Chen Feibiao and securities affairs representative Dai Yiyi attending to answer investor questions [1] - The A-share market has reached a total market value of over 116 trillion yuan, marking a significant milestone one year after the "9.24" event [1] - The article highlights four major transformations that are reshaping the new ecology of China's capital market [1]

Group 1: Pharmaceutical Business - The pharmaceutical business showed significant growth in the first half of the year, primarily due to concentrated shipments. The company continues to adhere to a major client strategy, focusing on CDMO business models and has established stable commercial relationships with several leading global pharmaceutical companies [1] - The company is actively expanding its client base, targeting strategic and high-viscosity clients, which is expected to drive further growth in the pharmaceutical sector as client product pipelines develop [1] Group 2: Agricultural Protection Business - The agricultural protection business is anticipated to recover in the second half of the year as the client inventory reduction cycle comes to an end. The business primarily focuses on CDMO, covering a range of products including insecticides, herbicides, and fungicides [1] - The company has over 20 years of experience in the agricultural protection industry and is recognized as a strategic partner by five major original research agricultural protection companies, providing comprehensive R&D, production, and supply chain solutions [1] Group 3: Overseas Subsidiaries - The UK subsidiary has improved its operational performance in the first half of the year, with increased capacity utilization and significant foreign exchange gains contributing to its revenue performance [2] - The Malaysian subsidiary is still under construction, with plans for it to focus on the production and sales of patented agricultural protection products once operational [2] Group 4: New Energy Business - The new energy business is expected to achieve significant progress this year, with collaborations established with several leading new energy companies, leading to stable supply and a substantial revenue breakthrough anticipated [2] - The company aims to optimize production and sales processes to reduce costs and enhance profitability in the new energy sector while also focusing on innovative product development [2] Group 5: Competitive Landscape - The company believes that Indian competitors cannot fully replace domestic suppliers, as clients seek to stabilize their supply chains through multi-regional sourcing [2] - China maintains a more comprehensive supply chain system, mature waste management processes, and a robust patent protection system, which provides a competitive edge in the international market [2]